The problems with delay discounting: a critical review of current practices and clinical applications
- PMID: 34184631
- PMCID: PMC8381235
- DOI: 10.1017/S0033291721002282
The problems with delay discounting: a critical review of current practices and clinical applications
Abstract
Delay discounting paradigms have gained widespread popularity across clinical research. Given the prevalence in the field, researchers have set lofty expectations for the importance of delay discounting as a key transdiagnostic process and a 'core' process underlying specific domains of dysfunction (e.g. addiction). We believe delay discounting has been prematurely reified as, in and of itself, a core process underlying psychological dysfunction, despite significant concerns with the construct validity of discounting rates. Specifically, high delay discounting rates are only modestly related to measures of psychological dysfunction and therefore are not 'core' to these more complex behavioral problems. Furthermore, discounting rates do not appear to be specifically related to any disorder(s) or dimension(s) of psychopathology. This raises fundamental concerns about the utility of discounting, if the measure is only loosely associated with most forms of psychopathology. This stands in striking contrast to claims that discounting can serve as a 'marker' for specific disorders, despite never demonstrating adequate sensitivity or specificity for any disorder that we are aware of. Finally, empirical evidence does not support the generalizability of discounting rates to other decisions made either in the lab or in the real-world, and therefore discounting rates cannot and should not serve as a summary measure of an individual's decision-making patterns. We provide recommendations for improving future delay discounting research, but also strongly encourage researchers to consider whether the empirical evidence supports the field's hyper-focus on discounting.
Keywords: Alcohol; RDoC; behavioral economics; construct validity; decision-making; delay discounting; impulsivity; substance use; transdiagnostic.
Conflict of interest statement
None.
Comment in
-
The fundamental questions left unanswered: response to commentary on the 'problems with delay discounting'.Psychol Med. 2023 Mar;53(4):1660-1661. doi: 10.1017/S0033291721005572. Epub 2022 Feb 4. Psychol Med. 2023. PMID: 35118936 No abstract available.
-
Unsparing self-critique strengthens the field, but Bailey et al. overstate the 'problems with delay discounting'.Psychol Med. 2023 Mar;53(4):1658-1659. doi: 10.1017/S0033291721005286. Epub 2022 Feb 28. Psychol Med. 2023. PMID: 35225188 Free PMC article. No abstract available.
References
-
- Athamneh, L. N., Freitas Lemos, R., Basso, J. C., Tomlinson, D. C., Craft, W. H., Stein, M. D., … Bickel, W. K. (2020). The phenotype of recovery II: The association between delay discounting, self-reported quality of life, and remission status among individuals in recovery from substance use disorders. Experimental and Clinical Psychopharmacology. Advance online publication. 10.1037/pha0000389. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous